These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 32703486)
1. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis. Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis. Hu H; Zhou C; Li B; Chen Y; Dai J; Mao Y; Huang T; Yu H; Chen M; Zhao J; Duan S Pathol Res Pract; 2018 Oct; 214(10):1572-1578. PubMed ID: 30082160 [TBL] [Abstract][Full Text] [Related]
3. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Nilsson TK; Löf-Öhlin ZM; Sun XF Int J Oncol; 2013 Jan; 42(1):127-33. PubMed ID: 23128528 [TBL] [Abstract][Full Text] [Related]
4. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062 [TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies. Wang HL; Liu P; Zhou PY; Zhang Y Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386 [TBL] [Abstract][Full Text] [Related]
6. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy. Sun X; Yuan W; Hao F; Zhuang W Med Sci Monit; 2017 Nov; 23():5389-5395. PubMed ID: 29128865 [TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis. Wang HL; Zhang Y; Liu P; Zhou PY Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684 [TBL] [Abstract][Full Text] [Related]
8. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis. Wen G; Wang H; Zhong Z Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221 [TBL] [Abstract][Full Text] [Related]
9. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831 [TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA). Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521 [TBL] [Abstract][Full Text] [Related]
11. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis. Shi DT; Han M; Gao N; Tian W; Chen W Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879 [TBL] [Abstract][Full Text] [Related]
12. [Methylation status of PCDH10 and RASSF1A gene promoters in colorectal cancer]. Li M; Yan DG; Liu JL Zhonghua Yi Xue Za Zhi; 2016 Feb; 96(6):456-9. PubMed ID: 26875923 [TBL] [Abstract][Full Text] [Related]
13. Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis. Guo Y; Long J; Lei S J Cell Physiol; 2019 May; 234(5):7356-7367. PubMed ID: 30370527 [TBL] [Abstract][Full Text] [Related]
14. β-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients. Chen SP; Wu CC; Huang SY; Kang JC; Chiu SC; Yang KL; Pang CY Genet Test Mol Biomarkers; 2012 Nov; 16(11):1277-81. PubMed ID: 23009572 [TBL] [Abstract][Full Text] [Related]
15. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007 [TBL] [Abstract][Full Text] [Related]
16. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202 [TBL] [Abstract][Full Text] [Related]
17. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847 [TBL] [Abstract][Full Text] [Related]
18. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA). Niu H; Yang J; Yang K; Huang Y Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283 [TBL] [Abstract][Full Text] [Related]
19. Association Between Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003 [TBL] [Abstract][Full Text] [Related]
20. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis. Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]